Search Results - "Del Barco Berrón, Sonia"
-
1
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
Published in Cancers (29-11-2022)“…Luminal advanced breast cancer (ABC) patients eventually progress on endocrine therapy. REVERT aimed to explore whether eribulin could restore endocrine…”
Get full text
Journal Article -
2
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Published in Clinical & translational oncology (01-09-2023)“…High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO…”
Get full text
Journal Article -
3
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Published in Clinical & translational oncology (01-04-2022)“…Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the…”
Get full text
Journal Article -
4
Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer
Published in Breast (Edinburgh) (01-10-2020)“…Metastatic breast cancer (MBC) diagnosis in young women negatively impacts on quality of life (QoL) and daily activities, disrupting their life project and…”
Get full text
Journal Article -
5
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Published in The lancet oncology (01-10-2017)“…Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole…”
Get full text
Journal Article -
6
Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study
Published in Clinical & translational oncology (01-11-2024)“…Precision medicine represents a paradigm shift in oncology. Access to genetic testing and targeted therapies is frequently limited. Assays based on DNA…”
Get full text
Journal Article -
7
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Published in Journal of clinical oncology (10-11-2015)“…Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a…”
Get full text
Journal Article -
8
SEOM clinical guidelines for the treatment of early breast cancer
Published in Clinical & translational oncology (01-11-2010)“…The incidence is increasing due to mammographic screening and an ageing population. In some countries the mortality rate has decreased especially in middleaged…”
Get full text
Journal Article -
9
Gene fusions in glioblastoma: Results of Gliocat project
Published in Journal of clinical oncology (20-05-2021)“…Abstract only 2042 Background: Malignant gliomas are heterogeneous diseases in genetic basis. The development of sequencing techniques, such as RNA-Sequencing,…”
Get full text
Journal Article -
10
Elderly glioblastoma patients: Survival analysis according adjuvant therapy and tumor molecular analysis
Published in Journal of clinical oncology (20-05-2021)“…Abstract only e14046 Background: Glioblastoma (GBM) grade IV represents the most frequent and aggressive primary brain tumor. Despite complete surgical…”
Get full text
Journal Article -
11
Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database
Published in Journal of clinical oncology (20-05-2021)“…Abstract only e14047 Background: Glioblastoma (GBM) is the most common brain primary tumor. Almost all patients have recurrent disease after initial treatment…”
Get full text
Journal Article -
12
Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles
Published in Journal of clinical oncology (20-05-2021)“…Abstract only 2013 Background: We previously presented our results of the GEINO 1401 trial that randomized patients diagnosed with glioblastoma and treated…”
Get full text
Journal Article -
13
Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 2029 Background: Glioblastoma (GBM) gene expression subtypes have been described in last years, data in homogeneously treated patients is…”
Get full text
Journal Article -
14
Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 2001 Background: The GEINO-14-01 trial (NCT02209948) investigated the role of extending temozolomide (TMZ) for 6 cycles after the standard 6…”
Get full text
Journal Article